CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2024-08-19
Cited: 0
Clicked: 1128
Yang YANG, Xiaolin GU, Jingsong HE, Yongxian HU, Zhen CAI. Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2300835 @article{title="Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy", %0 Journal Article TY - JOUR
华氏巨球蛋白血症:抗CD19嵌合抗原受体T细胞疗法治疗的挑战性病例1浙江大学医学院第一附属医院血液科骨髓移植中心,中国杭州市,310006 2浙江省舟山市普陀人民医院血液科,中国舟山市,316100 摘要:华氏巨球蛋白血症(WM)是一种罕见的小淋巴细胞、浆细胞样淋巴细胞和浆细胞肿瘤,会累及骨髓,甚至累及淋巴结和脾,通常与克隆性IgM球蛋白血症相关。尽管WM通常伴有惰性临床病程,但却无法治愈。本研究报告了一个具有挑战性的WM案例。该患者在化疗、免疫治疗和布鲁顿酪氨酸激酶(BTK)抑制剂治疗后出现复发/难治性病变,并累及髓外,但在CD19定向嵌合抗原受体T(CAR-T)细胞治疗后病情得到改善。此外,我们还回顾了文献中报道的CAR-T细胞治疗WM病例。本案例中的患者已接受一年多的随访,其病情仍保持良好的部分缓解状态,这表明CAR-T细胞疗法具有作为复发/难治性WM替代方案的潜力。人们迫切希望进行更大规模的临床研究来评估这种疗法的有效性和安全性。 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]AbeykoonJP,ZanwarS,AnsellSM,et al.,2021.Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.Am J Hematol,96(8):945-953. ![]() [2]BansalR,JurcicJG,SawasA,et al.,2020.Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia.Leuk Lymphoma,61(2):465-468. ![]() [3]CastilloJJ,MeidK,FlynnCA,et al.,2020.Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.Blood Adv,4(16):3952-3959. ![]() [4]CastilloJJ,AllanJN,SiddiqiT,et al.,2022.Venetoclax in previously treated Waldenström macroglobulinemia.J Clin Oncol,40(1):63-71. ![]() [5]GertzMA,2023.Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.Am J Hematol,98(2):348-358. ![]() [6]KastritisE,MorelP,DuhamelA,et al.,2019.A revised international prognostic score system for Waldenström’s macroglobulinemia.Leukemia,33(11):2654-2661. ![]() [7]KyriakouC,2018.High-dose therapy and hematopoietic stem cell transplantation in Waldenström macroglobulinemia.Hematol Oncol Clin North Am,32(5):865-874. ![]() [8]LockeFL,GhobadiA,JacobsonCA,et al.,2019.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol,20(1):31-42. ![]() [9]OwenRG,TreonSP,Al-KatibA,et al.,2003.Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia.Semin Oncol,30(2):110-115. ![]() [10]PalombaML,QuallsD,MonetteS,et al.,2022.CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.J Immunother Cancer,10(2):e004128. ![]() [11]RuanG,ZanwarS,AbeykoonJP,et al.,2020.Predictors of short-term survival in Waldenström macroglobulinemia.Leuk Lymphoma,61(12):2975-2979. ![]() [12]ShadmanM,YeungC,RedmanMW,et al.,2023.CD20 CAR-T therapy with MB-106 for BTK inhibitor-refractory Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) ‒ single institution study. HemaSphere,7(S3):e68877ca. ![]() [13]ThompsonPA,TamCS,2023.Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.Blood,141(26):3137-3142. ![]() [14]TreonSP,2015.How I treat Waldenström macroglobulinemia.Blood,126(6):721-732. ![]() [15]TreonSP,TedeschiA,San-MiguelJ,et al.,2023.Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom’s macroglobulinemia on diagnostic and response criteria.Semin Hematol,60(2):97-106. ![]() Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2025 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>